700 related articles for article (PubMed ID: 308870)
21. Efficacy and tolerability of currently available therapies for the mycosis fungoides and Sezary syndrome variants of cutaneous T-cell lymphoma.
Whittaker SJ; Foss FM
Cancer Treat Rev; 2007 Apr; 33(2):146-60. PubMed ID: 17275192
[TBL] [Abstract][Full Text] [Related]
22. The Microenvironment's Role in Mycosis Fungoides and Sézary Syndrome: From Progression to Therapeutic Implications.
Pileri A; Guglielmo A; Grandi V; Violetti SA; Fanoni D; Fava P; Agostinelli C; Berti E; Quaglino P; Pimpinelli N
Cells; 2021 Oct; 10(10):. PubMed ID: 34685762
[TBL] [Abstract][Full Text] [Related]
23. Mycosis fungoides and Sézary syndrome: Current challenges in assessment, management and prognostic markers.
Hughes CF; Newland K; McCormack C; Lade S; Prince HM
Australas J Dermatol; 2016 Aug; 57(3):182-91. PubMed ID: 25988337
[TBL] [Abstract][Full Text] [Related]
24. T-cell receptor gene rearrangement analysis: cutaneous T cell lymphoma, peripheral T cell lymphoma, and premalignant and benign cutaneous lymphoproliferative disorders.
Zelickson BD; Peters MS; Muller SA; Thibodeau SN; Lust JA; Quam LM; Pittelkow MR
J Am Acad Dermatol; 1991 Nov; 25(5 Pt 1):787-96. PubMed ID: 1839392
[TBL] [Abstract][Full Text] [Related]
25. [Comparative analysis of the cell composition of the infiltrate in malignant lymphoma of the skin].
Prikolab IP; Ivanov AA
Ter Arkh; 1987; 59(12):91-6. PubMed ID: 3502296
[TBL] [Abstract][Full Text] [Related]
26. Myocosis fungoides--an update on a non-mycotic disease.
Makdisi J; Friedman A
J Drugs Dermatol; 2013 Jul; 12(7):825-31. PubMed ID: 23884501
[TBL] [Abstract][Full Text] [Related]
27. [Cells in the epidermotropic lymphomas (mycosis fungoides and Sézary syndrome. Study using monoclonal antibodies].
Thivolet J; Schmitt D; Souteyrand P; Brochier J
Nouv Presse Med; 1982 Oct; 11(41):3033-8. PubMed ID: 6755391
[TBL] [Abstract][Full Text] [Related]
28. Therapy of cutaneous lymphoma--current practice and future developments.
Dummer R; Kempf W; Hess Schmid M; Häffner A; Burg G
Onkologie; 2003 Aug; 26(4):366-72. PubMed ID: 12972705
[TBL] [Abstract][Full Text] [Related]
29. [Mycosis fungoides and Sézary syndrome : a systematic review].
André F; Guenova E; Blanchard G
Rev Med Suisse; 2022 Mar; 18(775):578-589. PubMed ID: 35353453
[TBL] [Abstract][Full Text] [Related]
30. Absence of T(H)2 cytokine messenger RNA expression in CD30-negative primary cutaneous large T-cell lymphomas.
Vermeer MH; Tensen CP; van der Stoop PM; van Oostveen HW; Lund M; Scheper RJ; Willemze R
Arch Dermatol; 2001 Jul; 137(7):901-5. PubMed ID: 11453809
[TBL] [Abstract][Full Text] [Related]
31. Is bone marrow biopsy necessary in patients with mycosis fungoides and Sézary syndrome? A histological and molecular study at diagnosis and during follow-up.
Beylot-Barry M; Parrens M; Delaunay M; Thiebault R; Vergier B; DeMascarel A; Dubus P; Beylot C; Merlio JP
Br J Dermatol; 2005 Jun; 152(6):1378-9. PubMed ID: 15949023
[No Abstract] [Full Text] [Related]
32. Lymphoma and leukemia of t-lymphocytes.
Watanabe S; Shimosato Y; Shimoyama M
Pathol Annu; 1981; 16(Pt 2):155-203. PubMed ID: 7036059
[No Abstract] [Full Text] [Related]
33. Report of the Committee on Staging and Classification of Cutaneous T-Cell Lymphomas.
Bunn PA; Lamberg SI
Cancer Treat Rep; 1979 Apr; 63(4):725-8. PubMed ID: 445521
[No Abstract] [Full Text] [Related]
34. Report of the Committee on Pathology of Cutaneous T Cell Lymphomas.
Clendenning WE; Rappaport HW
Cancer Treat Rep; 1979 Apr; 63(4):719-24. PubMed ID: 376141
[No Abstract] [Full Text] [Related]
35. [Clinical characteristics of mycosis fungoides and Sézary syndrome].
Krc L; Dobesová J; Bucek M; Dusek J; Macák J; Galuszková D; Jurysek O
Vnitr Lek; 1997 May; 43(5):285-9. PubMed ID: 9601850
[TBL] [Abstract][Full Text] [Related]
36. [Immunological characterization of malignant epidermotropic lymphoma cells in cutaneous infiltrates (author's transl)].
Thivolet J; Souteyrand P; Alario A; Schmitt D; Perrot H
Dermatologica; 1978; 157(6):357-64. PubMed ID: 363474
[TBL] [Abstract][Full Text] [Related]
37. Cytologic evaluation of lymphadenopathy associated with mycosis fungoides and Sezary syndrome: role of immunophenotypic and molecular ancillary studies.
Pai RK; Mullins FM; Kim YH; Kong CS
Cancer; 2008 Oct; 114(5):323-32. PubMed ID: 18798522
[TBL] [Abstract][Full Text] [Related]
38. Programmed death 1 is expressed in cutaneous infiltrates of mycosis fungoides and Sézary syndrome.
Wada DA; Wilcox RA; Harrington SM; Kwon ED; Ansell SM; Comfere NI
Am J Hematol; 2011 Mar; 86(3):325-7. PubMed ID: 21328438
[No Abstract] [Full Text] [Related]
39. Status report of 376 mycosis fungoides patients at 4 years: Mycosis Fungoides Cooperative Group.
Lamberg SI; Green SB; Byar DP; Block JB; Clendenning WE; Epstein EH; Fuks ZY; Golitz LE; Lorincz AL; Michel B; Roenigk HH; Van Scott EJ; Vonderheid EC; Thomas RJ
Cancer Treat Rep; 1979 Apr; 63(4):701-7. PubMed ID: 376140
[TBL] [Abstract][Full Text] [Related]
40. Mycosis fungoides and the Sézary syndrome: pathology, staging, and treatment.
Hoppe RT; Wood GS; Abel EA
Curr Probl Cancer; 1990; 14(6):293-371. PubMed ID: 2245651
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
